Brent Chesson

Brent Chesson, PhD, is a Principal Scientist at Immatics Biotechnologies, where they focus on cancer immunotherapy. Previously, Brent completed a PhD in Human Pathophysiology and Translational Medicine at UTMB, where their dissertation researched self-assembling peptides for vaccine development. Brent also served as a Post-doctoral Research Fellow at the Rutgers Cancer Institute of New Jersey and MD Anderson Cancer Center, concentrating on tumor immunology and melanoma oncology, respectively. Additionally, they have experience in vaccine policy research with the World Health Organization. Brent holds multiple degrees, including a Bachelor of Science in Chemistry and a Master of Public Health from UTMB.